An Australian Patent Opposition, Revocation and Extension of Term Round-Up from the Patent Office Journal dated 23 May 2013.
If you wish to oppose the grant of a patent, or if your grant own application has been opposed by third parties, please contact us.
Please note that the information in the tables below is correct as at the date of the Patent Office Journal but is subject to change. Please check AUSPAT for the current status of any of the patents below.
Opposition Proceedings
Opposition Lodged
Acceptance of the following patent applications has been opposed:
| Application No. | Title | Applicant(s) | Opponent(s) |
| 2008306060 | Beverage brewing unit | Nestec S.A. | Koninklijke Douwe Egberts B.V. |
Opposition Withdrawn
Opposition to acceptance of the following applications has been withdrawn, and the application shall proceed to sealing:
| Application No. | Title | Applicant(s) | Opponent(s) |
| 2004294810 | In ovo vaccination of Campylobacter in avian species | Pfizer Products Inc. | Merial Ltd |
| 2006226304 | Process for microbial production of a valuable compound | DSM IP Assets B.V. | BASF SE |
| 2009243527 | Controlled release formulation | Euro-Celtique S.A. | Southern Cross Pharma Pty Ltd |
Opposition Dismissed
No additional opposition proceedings have been dismissed.
Applications Withdrawn
No additional applications have been withdrawn following opposition.
Extensions of Term of Standard Patents
Applications Filed
The following applications for Extension of Term under Section 70 have been made:
| Patent No. | Title | Patentee(s) | First Reg Approval Date & Goods |
| 2002231970 | Mucoadhesive pharmaceutical formulations | GW Pharma Limited | 26 Nov 2012For the goods SATIVEX nabiximols |
| 2003253005 | Cannabinoid liquid formulations for mucosal administration | GW Pharma Limited | 26 Nov 2012For the goods SATIVEX nabiximols |
| 2009202434 | Cannabinoid liquid formulations for mucosal administration | GW Pharma Limited | 26 Nov 2012For the goods SATIVEX nabiximols |
Applications Accepted
The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.
| Patent No. | Title | Patentee(s) | First Reg Approval Date & Goods | Address for Service |
| 2003237886 | C-aryl glucoside SGLT2 inhibitors and method | Bristol-Myers Squibb Company | 22 Oct 2012For the goods FORXIGA dapagliflozin | Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000 |
Extensions granted
No additional applications for Extension of Term have been granted under Section 76.
Surrendered and Revoked Letters Patent
Surrendered Letters Patent
No patents have been offered for surrender.
Revocation of Letters Patent
No additional patents have been wholly or partially revoked.